Points of Clarity - Clinical Programs
The purpose of Nu-Life clinical programs or initiatives are to demonstrate that Nu-V3 and the Nu-V3 program is comprehensive, safe, effective, simple to apply and easy to use.
Nu-V3 initiatives and clinical programs are Institutional Review Board (IRB) approved clinical trials and abide by all regulatory requirements and oversight by IRB, clinical principal investigators and our clinical team.
Although the Nu-V3 clinical programs are performed under strict regulatory standards, the clinical background and data necessary for FDA clearance has already been documented and finalized.
The Nu-Life regulatory strategy has been designed specifically to meet the goals and objectives for Nu-V3 in the United States as well as the regions of Europe, Japan, Latin America and Canada, all of which carry their own specific regulatory requirements.
To view our major points of clarity with regard to the Nu-Life regulatory strategy, please click below.